CDP 860

Drug Profile

CDP 860

Alternative Names: anti-PDGF beta receptor antibody; anti-platelet derived growth factor beta receptor antibody

Latest Information Update: 30 Mar 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Washington; ZymoGenetics
  • Developer Nektar Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Intercellular signalling peptide and protein inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Coronary artery restenosis

Most Recent Events

  • 30 Mar 2004 Discontinued - Phase-II for Cancer in United Kingdom (unspecified route)
  • 16 Jun 2003 CDP 860 is available for partnering (
  • 29 Oct 2002 Inhale Therapeutic Systems and Celltech have entered into a licensing, manufacturing and supply agreement for CDP 860
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top